SubsidieMeestersFirst-in-class anti-PVR mAb NTX1088 - a novel oncology drug that unlocks the power of human immune system and revolutionizes cancer care
Nectin Therapeutics is developing NTX1088, a monoclonal antibody that activates the immune system against cancer, currently in Phase I trials to improve patient outcomes in oncology.
Projectdetails
Introduction
Nectin Therapeutics (NectinTx) is a venture-backed company with a top-notch team focused on innovative therapeutic options for cancer patients.
Pipeline Development
To address the limitations of available therapies, the company has developed a diverse pipeline of antibodies that overcome immune inhibitory pathways deployed by the tumors.
NTX1088
NTX1088 is a monoclonal antibody that binds human poliovirus receptor (PVR) and activates the patient’s immune system to fight cancer through a triple mechanism of action never demonstrated before.
Preclinical Data
A comprehensive preclinical dataset was generated to show the robust antitumor activity of NTX1088 in vitro and in vivo.
Clinical Trials
Following IND approval and strong backing from key opinion leaders, the Phase I clinical trial has commenced, aimed to enroll patients with solid tumors.
Market Impact
The project will accelerate the clinical development of NTX1088 towards a novel therapy in the €80 billion immune-oncology drug market, resulting in better outcomes for patients and reduced societal and economic burden associated with cancer.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.998 |
| Totale projectbegroting | € 3.571.427 |
Tijdlijn
| Startdatum | 1-8-2024 |
| Einddatum | 31-1-2028 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- NECTIN THERAPEUTICS LTDpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Inhibiting resistance to immunotherapy in Oncology by targeting Netrin-1The IMMUNONET project aims to clinically test NP137, a monoclonal antibody that enhances response to immune checkpoint inhibitors in cancer patients resistant to current treatments. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Innovative approach to an Individualised T-Cell Immunotherapy for cancer, using Personalised Tumour Trained Lymphocytes (pTTL) that is reliable, cost-effective, scalable and easy to implementNEOGAP's project aims to develop a personalized T cell therapy for solid tumors using machine learning and neoantigen stimulation, with a focus on safety and biomarker exploration in colorectal cancer trials. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Acceleration of the world’s first autotaxin inhibitor for the treatment of pancreatic cancer (PDAC)iOnctura aims to accelerate clinical trials for IOA-289, a novel autotaxin inhibitor targeting pancreatic cancer, to improve treatment outcomes and attract further investment. | EIC Accelerator | € 2.500.000 | 2022 | Details |
PAH-ADVANCE: Accelerating the Clinical Path of NTP42, a disease-modifying drug that will disrupt the future treatment of cardiopulmonary diseases, including pulmonary arterial hypertension (PAH).ATXA Therapeutics aims to advance NTP42, a novel drug for pulmonary arterial hypertension, through Phase II trials and licensing to accelerate market entry and diversify its drug portfolio. | EIC Accelerator | € 2.500.000 | 2023 | Details |
FIRST-IN-CLASS MYC INHIBITOR: THE MAKING OF A BREAKTHROUGH CANCER THERAPYMYCureX aims to evaluate the safety and efficacy of OMO-103, a novel MYC inhibitor, in combination with standard care for PDAC, while refining companion diagnostics for improved patient outcomes. | EIC Accelerator | € 2.494.504 | 2023 | Details |
Inhibiting resistance to immunotherapy in Oncology by targeting Netrin-1
The IMMUNONET project aims to clinically test NP137, a monoclonal antibody that enhances response to immune checkpoint inhibitors in cancer patients resistant to current treatments.
Innovative approach to an Individualised T-Cell Immunotherapy for cancer, using Personalised Tumour Trained Lymphocytes (pTTL) that is reliable, cost-effective, scalable and easy to implement
NEOGAP's project aims to develop a personalized T cell therapy for solid tumors using machine learning and neoantigen stimulation, with a focus on safety and biomarker exploration in colorectal cancer trials.
Acceleration of the world’s first autotaxin inhibitor for the treatment of pancreatic cancer (PDAC)
iOnctura aims to accelerate clinical trials for IOA-289, a novel autotaxin inhibitor targeting pancreatic cancer, to improve treatment outcomes and attract further investment.
PAH-ADVANCE: Accelerating the Clinical Path of NTP42, a disease-modifying drug that will disrupt the future treatment of cardiopulmonary diseases, including pulmonary arterial hypertension (PAH).
ATXA Therapeutics aims to advance NTP42, a novel drug for pulmonary arterial hypertension, through Phase II trials and licensing to accelerate market entry and diversify its drug portfolio.
FIRST-IN-CLASS MYC INHIBITOR: THE MAKING OF A BREAKTHROUGH CANCER THERAPY
MYCureX aims to evaluate the safety and efficacy of OMO-103, a novel MYC inhibitor, in combination with standard care for PDAC, while refining companion diagnostics for improved patient outcomes.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
C- and N-terminal Epitope Conjugate immune Cell Targeted VaccinesCNECT-VAX aims to validate a novel cancer vaccine platform using nanobodies for targeted dendritic cell activation to enhance immune responses and improve treatment efficacy. | ERC Proof of... | € 150.000 | 2022 | Details |
Nanobodies blocking immunosuppressive unexplored proteins from the tumor endothelium to promote anti-tumor immune responseThis project aims to develop novel nanobody therapeutics targeting unexplored immunosuppressive genes in endothelial cells to enhance anti-tumor immunity in non-small cell lung cancer. | ERC Proof of... | € 150.000 | 2025 | Details |
Allosteric modulation of immune checkpoint complexes as a new mode of therapeutic intervention in immunotherapyThe project aims to develop novel Nanobodies as safe and effective modulators of immune checkpoint complexes for cancer and autoimmune diseases, potentially outperforming current therapies. | ERC Advanced... | € 2.499.674 | 2024 | Details |
Modular Targeted Nanoplatform for Immune Cell Regulation and TherapyImmuNovation aims to develop a targeted nano-immunoModulator nanovaccine to enhance antitumor immunity against CEACAM5+ gastrointestinal cancers, offering a safer and more effective treatment alternative. | ERC Proof of... | € 150.000 | 2023 | Details |
RESTORING IMMUNITY CONTROL OF GI CANCERSTIMNano aims to develop a novel cancer immunotherapy platform using targeted biodegradable nanoparticles to enhance immune responses against gastrointestinal cancers, progressing through clinical trials and commercialization. | EIC Transition | € 2.007.750 | 2025 | Details |
C- and N-terminal Epitope Conjugate immune Cell Targeted Vaccines
CNECT-VAX aims to validate a novel cancer vaccine platform using nanobodies for targeted dendritic cell activation to enhance immune responses and improve treatment efficacy.
Nanobodies blocking immunosuppressive unexplored proteins from the tumor endothelium to promote anti-tumor immune response
This project aims to develop novel nanobody therapeutics targeting unexplored immunosuppressive genes in endothelial cells to enhance anti-tumor immunity in non-small cell lung cancer.
Allosteric modulation of immune checkpoint complexes as a new mode of therapeutic intervention in immunotherapy
The project aims to develop novel Nanobodies as safe and effective modulators of immune checkpoint complexes for cancer and autoimmune diseases, potentially outperforming current therapies.
Modular Targeted Nanoplatform for Immune Cell Regulation and Therapy
ImmuNovation aims to develop a targeted nano-immunoModulator nanovaccine to enhance antitumor immunity against CEACAM5+ gastrointestinal cancers, offering a safer and more effective treatment alternative.
RESTORING IMMUNITY CONTROL OF GI CANCERS
TIMNano aims to develop a novel cancer immunotherapy platform using targeted biodegradable nanoparticles to enhance immune responses against gastrointestinal cancers, progressing through clinical trials and commercialization.